Related Experiment Video
Updated: Dec 30, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient
Ana Belén Lozano1, Natalia Chueca2, Adolfo de Salazar2
1Hospital de Poniente, El Ejido, Almería, Spain.
Abstract:
We present here one of the first cases of virological failure during treatment with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). On March 2019, an antiretroviral-experienced HIV-infected patient was admitted to hospital because of cerebral toxoplasmosis. After undergoing treatment with sulfadiazine-pyrimethamine for two weeks, the patient initiated a BIC/FTC/TAF treatment, with 6.01 HIV RNA Log copies/mL, and 37 CD4 cells/μL. After two months under antiretroviral therapy (ART), acute neurologic deterioration with epilepsy, right hemiparesis and dysphagia occurred, leading to nasogastric nutrition and treatment. After several weeks, virological failure was confirmed with 4.01 HIV RNA Log copies/mL and R263K and M184V resistance mutations were detected.
Related Concept Videos
Retrovirus Life Cycles
Viral Mutations
Pharmacokinetics in Pediatric Patients: Drug Excretion
Retroviruses
Development of Antibiotic Resistance
Treatment Resistant Cancers

